Mesenchymal Cell News Volume 14.26 | Jul 5 2022

    By
    Bob
    -
    0
    21







    2022-07-05 | MESCN 14.26


    Mesenchymal Cell News by STEMCELL Technologies
    Vol. 14.26 – 5 July, 2022
    TOP STORY

    Mesenchymal Stromal Cells Overexpressing Farnesoid X Receptor Exert Cardioprotective Effects Against Acute Ischemic Heart Injury by Binding Endogenous Bile Acids

    Investigators found that overexpression of farnesoid X receptor, a main receptor for bile acids, improved the retention and cardioprotection of adipose tissue-derived MSCs administered by intramyocardial injection in mice with myocardial infarction.
    [Advanced Science]

    Full Article
    Request your free copy of the 'Directed Differentiation of Pluripotent Stem Cells' Wallchart
    PUBLICATIONSRanked by the impact factor of the journal

    Generation of Hyaline-Like Cartilage Tissue from Human Mesenchymal Stromal Cells within the Self-Generated Extracellular Matrix

    Results indicated that human MSC-derived cartilage formed in hypoxic culture displayed a significantly reduced hypertrophy level than normoxic culture.
    [Acta Biomaterialia]

    AbstractGraphical Abstract

    Hypoxic Condition Induced H3K27me3 Modification of the LncRNA Tmem235 Promoter Thus Supporting Apoptosis of BMSCs

    H3K27me3 cooperated with LncRNA Tmem235 promoter DNA methylation to inhibit the expression of LncRNA Tmem235 and promoted the apoptosis of bone marrow MSCs.
    [Apoptosis]

    Full Article

    Monovalent Ions and Stress-Induced Senescence in Human Mesenchymal Endometrial Stem/Stromal Cells

    Human mesenchymal endometrium stem/stromal cells subjected to oxidative stress entered into premature senescence accompanied by persistent DNA damage, irreversible cell cycle arrest, increased expression of the cell cycle inhibitors cell hypertrophy, and enhanced β-galactosidase activity.
    [Scientific Reports]

    Full Article

    MiR-29a-3p Inhibits Proliferation and Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells via Targeting FOXO3 and Repressing Wnt/β-Catenin Signaling in Steroid-Associated Osteonecrosis

    Researchers investigated the role of miR-29a-3p in human bone marrow MSCs, and its relationship with steroid-associated osteonecrosis.
    [International Journal of Stem Cells]

    Abstract

    Modulation of Osteogenic Differentiation of Adipose-Derived Stromal Cells by Co-Treatment with 3, 4’-Dihydroxyflavone, U0126, and N-Acetyl Cysteine

    Scientists investigated the effect of a flavonoid, 3, 4’-dihydroxyflavone on osteogenic differentiation of equine adipose-derived stromal cells.
    [International Journal of Stem Cells]

    Abstract

    MicroRNA-25-3p Suppresses Osteogenic Differentiation of BMSCs in Patients with Osteoporosis by Targeting ITGB3

    The authors investigated the impact of the miR-25–3p/integrin beta-3 (ITGB3) axis on the osteogenic differentiation of bone marrow MSCs (BMSCs) in patients with osteoporosis.
    [Acta Histochemica]

    Abstract

    A Regulatory Mechanism of a Stepwise Osteogenesis-Mimicking Decellularized Extracellular Matrix on the Osteogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells

    Four types of stepwise decellularized extracellular matrices were prepared from bone marrow-derived MSCs undergoing osteogenic differentiation for 0, 7, 14, and 21 days after decellularization.
    [Journal of Materials Chemistry B]

    AbstractGraphical Abstract

    EMF Promote BMSCs Differentiation and Functional Recovery in Hemiparkinsonian Rats

    Scientists focused on the electromagnetic field (EMF) exposed multi-potential bone marrow MSCs which differentiated and successfully implanted in the substantia nigra pars compacta of Parkinson’s disease rat model.
    [Neuroscience Letters]

    Abstract
    Explore tools and resources for your return to the lab
    REVIEWS

    Translating MSC Therapy in the Age of Obesity

    Investigators look to cancer immunotherapy as a model for the challenges MSCs may face in obese environments.
    [Frontiers in Immunology]

    Full Article
    INDUSTRY AND POLICY NEWS

    BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase II Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

    BioRestorative Therapies, Inc. announced that the first patient has been enrolled in the company’s Phase II clinical trial evaluating the safety and preliminary efficacy of BRTX-100, an autologous bone marrow-derived MSC targeting chronic lumbar disc disease.
    [BioRestorative Therapies, Inc. (GlobeNewswire, Inc.)]

    Press Release

    FEATURED EVENT

    3D Cell Culture Symposium

    December 1, 2022
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Sarcoma Pathology

    The University of Iowa – Iowa City, Iowa, United States

    Postdoctoral Researcher – Cartilage Regeneration

    University Medical Center Utrecht – Utrecht, Netherlands

    PhD Scholarship – Enhancers Communities

    University of Southern Denmark – Odense M, Denmark

    Postdoctoral Researcher – Immunomodulation

    National University of Ireland Galway – Galway, Ireland

    Postdoctoral Position – Cancer Biology and Immunotherapies

    Sanford Research – Sioux Falls, South Dakota, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mesenchymal Cell News Twitter